Shahin Davoudpour, PhD, MA, MA, discusses the challenges associated with access to and persistence with pre-exposure ...

Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...

The medication, Lenacapavir, is said to have shown exceptional promise in clinical trials, and some of the research is being conducted here in Houston.

In 2021, approval of cabotegravir (Apretude) as the first long-acting PrEP option provided patients an option to move from ...

The NHS is calling for 200,000 new donors to come forward as it warns of a "challenging" blood supply shortage. Currently ...

Quezon City recorded 421 new human immunodeficiency virus (HIV) cases from January to May this year. That is over 7.7 percent ...

A Houston physician has sued the federal government to cut benefits through the Affordable Care Act that requires access to ...

The PURPOSE trials illuminated the ways in which lenacapavir could be used as a means of pre-exposure prophylaxis effectively, but also featured several adverse events.

Updated CDC guidelines on PEP after nonoccupational HIV exposure address newer ART agents and clinical considerations for patients with a history of long-acting ART.

The Kerala Government Medical Officers’ Association (KGMOA) has demanded that a pre-exposure prophylaxis (PrEP) programme be rolled out in the wake of an increase in rabies deaths in the State.